Central line-associated bloodstream infections caused by Staphylococcus aureus in cancer patients: Clinical outcome and management

Ann Med. 2014 May;46(3):163-8. doi: 10.3109/07853890.2013.878513. Epub 2014 Feb 4.

Abstract

Background: There are limited data regarding clinical presentation and management of Staphylococcus aureus central line- associated bloodstream infection (CLABSI) in immunocompromised cancer patients.

Methods: In this review, we evaluated 299 patients with 304 episodes of S. aureus-CLABSI between 2005 and 2011.

Findings: By multivariate analysis, the major predictors of complicated S. aureus-CLABSI were septic shock, catheter site inflammation, presence of peripherally inserted central catheter, anti-cancer chemotherapy within 10 days, and persistent bacteremia beyond 72 hours (P ≤ 0.02). A total of 67% of the cases were defined as complicated. In the subset of patients who were uncomplicated on presentation, patients receiving antimicrobials ≥ 14 days had similar rates of relapse, attributable mortality, and development of complications compared to those receiving shorter-course therapy. By competing risk analysis, removal of the catheter within 3 days of the onset of bacteremia was associated with a lower relapse rate at 90 days (P = 0.024).

Interpretation: The majority of S. aureus-CLABSI in cancer patients are complicated and require prolonged course of antimicrobial treatment. Early removal of the catheter within the first 3 days is associated with better course. In patients with prompt removal of the catheter and no evidence of a complicated course, treatment beyond 2 weeks may not be necessary.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bacteremia / etiology
  • Bacteremia / therapy*
  • Central Venous Catheters / adverse effects*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Neutropenia / complications
  • Retrospective Studies
  • Staphylococcal Infections / etiology
  • Staphylococcal Infections / therapy*
  • Staphylococcus aureus*
  • Young Adult